Showing 2762 results
- Media Release /Decision brings hope of longer and better life with fewer hospitalizations for millions of Europeans with symptomatic chronic heart failure with reduced ejection fraction Entresto is the…
- Media Release /Data suggest myelofibrosis (MF) patients treated with Jakavi® (ruxolitinib) after 5 years lived longer despite crossover from best available therapy after week 48[1] Phase III results show…
- Media Release /More than 50 abstracts will be presented, including data on Afinitor® and investigational compounds for advanced breast cancer, showing pipeline strength Presentations highlight results of…
- Media Release /Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute…
- Media Release /Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma Successful technology transfer enabling commercial scale-up of CTL019…
- Media Release /PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer. The study met…
- Media Release /55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults[1] Additional data presented include analyses on…
- Media Release /Sandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes…
- Media Release /Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300…
- Media Release /Cosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)…
Pagination
- ‹ Previous page
- 1
- …
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- …
- 277
- › Next page